(Q46527499)

22 December 2017

meta-analysis

0 references

title

Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival (English)

1 reference

22 December 2017

1 reference

1 reference

8

Patrick Hwu

1 reference

22 December 2017

author name string

Agop Y Bedikian

1

1 reference

22 December 2017

Marcella M Johnson

2

1 reference

22 December 2017

Carla L Warneke

3

1 reference

22 December 2017

Susan McIntyre

4

1 reference

22 December 2017

Nicholas Papadopoulos

5

1 reference

22 December 2017

Wen-Jen Hwu

6

1 reference

22 December 2017

Kevin Kim

7

1 reference

22 December 2017

publication date

1 April 2008

1 reference

22 December 2017

Journal of Immunotoxicology

published in

1 reference

22 December 2017

volume

5

1 reference

22 December 2017

issue

2

1 reference

22 December 2017

page(s)

201-207

1 reference

22 December 2017

Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)

cites work

1 reference

https://api.crossref.org/works/10.1080%2F15476910802131519

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802131519

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802131519

Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802131519

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802131519

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802131519

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802131519

Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802131519

Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802131519

A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802131519

Sequential chemoimmunotherapy in the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802131519

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802131519

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910802131519

10.1080/15476910802131519

21 January 2018

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017